Sign up to save your podcasts
Or
Share How to Treat Hormone Receptor Positive Cancer - Latest Advancements and Current Standard of Care in 2025
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
How to Treat Hormone Receptor Positive Cancer - Latest Advancements and Current Standard of Care in 2025
Welcome to the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain are joined by Dr. Kevin Kalinsky, a leading breast medical oncologist and director of the breast cancer program at the Winship Cancer Institute of Emory University.
Join us as we dive deep into the complexities of hormone receptor-positive breast cancer treatment. We discuss the latest advancements in treatment algorithms, including the use of OncotypeDX in premenopausal versus postmenopausal women, the role of ovarian function suppression, and the implications of new approvals like Inavolisib and CDK4-6 inhibitors.
Key topics covered in this episode:
• The significance of recurrence scores in dictating adjuvant chemotherapy
• The ongoing OFSET trial and its potential impact on treatment decisions
• Insights into the use of genomic assays like MammaPrint and RS-Clin
• The evolving landscape of treatment options for locally advanced and metastatic breast cancer
• The latest on PARP inhibitors, T-DXd, and other novel therapies
Whether you're a medical professional or someone interested in the latest in oncology, this episode is packed with valuable insights and clinical pearls. Don't forget to subscribe for more discussions on cancer treatment, FDA approvals, and conference highlights!
YouTube: https://youtu.be/_icBN3J3Bc0
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
#OncologyBrothers #HR+ #breastcancer #HormoneReceptorPositiveCancer #oncbrothers #Podcast
View all episodes
By Oncology Brothers
4.8
4040 ratings
Welcome to the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain are joined by Dr. Kevin Kalinsky, a leading breast medical oncologist and director of the breast cancer program at the Winship Cancer Institute of Emory University.
Join us as we dive deep into the complexities of hormone receptor-positive breast cancer treatment. We discuss the latest advancements in treatment algorithms, including the use of OncotypeDX in premenopausal versus postmenopausal women, the role of ovarian function suppression, and the implications of new approvals like Inavolisib and CDK4-6 inhibitors.
Key topics covered in this episode:
• The significance of recurrence scores in dictating adjuvant chemotherapy
• The ongoing OFSET trial and its potential impact on treatment decisions
• Insights into the use of genomic assays like MammaPrint and RS-Clin
• The evolving landscape of treatment options for locally advanced and metastatic breast cancer
• The latest on PARP inhibitors, T-DXd, and other novel therapies
Whether you're a medical professional or someone interested in the latest in oncology, this episode is packed with valuable insights and clinical pearls. Don't forget to subscribe for more discussions on cancer treatment, FDA approvals, and conference highlights!
YouTube: https://youtu.be/_icBN3J3Bc0
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
#OncologyBrothers #HR+ #breastcancer #HormoneReceptorPositiveCancer #oncbrothers #Podcast
More shows like Oncology Brothers: Practice-Changing Cancer Discussions
View all
NEJM This Week
322 Listeners
Journal of Clinical Oncology (JCO) Podcast
40 Listeners
Research To Practice | Oncology Videos
116 Listeners
ASCO Daily News
57 Listeners
Mayo Clinic Talks
288 Listeners
White Coat Investor Podcast
2,435 Listeners
The Curbsiders Internal Medicine Podcast
3,339 Listeners
Core IM | Internal Medicine Podcast
1,154 Listeners
The ONS Podcast
199 Listeners
OncoPharm
184 Listeners
ASCO Guidelines
44 Listeners
OncLive® On Air
21 Listeners
Becker’s Healthcare Podcast
189 Listeners
Oncology Today with Dr Neil Love
57 Listeners
Two Onc Docs
185 Listeners